红细胞膜仿生纳米药物载体在动脉粥样硬化治疗中的应用研究进展  

Research progress on the application of biomimetic nanocarriers functionalized with erythrocyte membrane for atherosclerosis therapy

作　　者：曹钰 牟年莲 朱力 王溢 王贵学[1] 吴伟[1] CAO Yu;MOU Nianlian;ZHU Li;WANG Yi;WANG Guixue;WU Wei(Key Laboratory for Biorheological Science and Technology of Ministry of Education&State and Local Joint Engineering Laboratory for Vascular Implants&Bioengineering College of Chongqing University,Chongqing 400030,China)

机构地区：[1]重庆大学医学部生物工程学院血管植入物开发国家地方联合工程实验室生物流变科学与技术教育部重点实验室,重庆市400030

出　　处：《中国动脉硬化杂志》2023年第1期1-8,共8页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金面上/重点项目(31971301、31971242和12032007);重庆市自然科学基金面上/重点项目(cstc2021jcyj-msxmX0149和cstc2019jcyj-zdxmX0028)。

摘　　要：近年来,利用细胞膜包被纳米粒子技术研发针对动脉粥样硬化治疗的仿生纳米药物成为研究的热点。在各种细胞膜中,由于红细胞独特的生物特性,红细胞膜成为用于纳米粒子包被的最常使用的细胞膜材料。利用红细胞膜包被的仿生纳米药物,不仅可以延长药物的体内循环时间、优化药物的生物相容性,还可通过动脉粥样硬化病变部位高通透性与滞留效应展现优异的被动靶向功能,从而实现药物对于病灶部位的高效递送;最终达到安全、高效的抗动脉粥样硬化治疗。基于此,文章综述了近些年关于红细胞膜包被技术在构建仿生纳米药物中的应用,聚焦其在动脉粥样硬化治疗中的研发应用。In recent years,the use of cell membrane-coated nanoparticles to develop biomimetic nanomedicines for atherosclerosis treatment has become a research hotspot.Among various cell membranes,due to the unique biological properties,red blood cells have been widely used as drug delivery.Erythrocyte membrane camouflaged biomimetic nanomedicines can not only prolong the circulation time and improve the biocompatibility in vivo,but also exhibit excellent passive targets through the enhanced permeability and retention effects of lesions for safe and efficient atherosclerosis therapy.Herein,this paper reviews erythrocyte membrane coating technology in the application of constructing the biomimetic nanomediciens in recent years,and focuses on its research applications in atherosclerosis therapy.

关 键 词：红细胞膜 纳米 仿生 药物载体 动脉粥样硬化 

分 类 号：R363[医药卫生—病理学] R5[医药卫生—基础医学]